Andy Boyes appointed as Non-Executive Director to Synapse Electroceutical Limited
Published : 21/12/2017
Synapse Electroceutical Limited is delighted to announce the appointment of Andy Boyes to the Board. Andy has enjoyed a successful, 32 year career at Smith & Nephew, the FTSE 100 medical technology business engaged in developing, manufacturing, marketing and selling medical devices in the Advanced Wound Management and Advanced Surgical Devices sectors with sales in excess of £4 billion. Andy is passionate
about the wound care sector and helping improve the lives of patients suffering with debilitating complex wounds and since leaving Smith & Nephew has focussed on providing Board level support and strategic direction in the sector.
For his last 10 years at Smith & Nephew, Andy led the Advanced Wound Management division in Europe with sales of £400 million, profit over £100 million and a strong market leadership position, as well as leading strategic initiatives across the wider group. Prior to this he set up an Innovation group including strategic marketing, R&D, project management, clinical trials and health economics functions, which led to several breakthrough developments and technology acquisitions. Andy has extensive experience of introducing innovative wound care products to the global market and successfully growing revenues for these products to over £100m.
Andy brings his deep industry knowledge to Synapse at a time of change in the sector. There is significantly increased scrutiny on the cost of wound care and, consequently, on healing rates and outcomes. The major players are under pressure as the traditional products that dominate the market are commoditised and sales and margins come under significant pressure. Through years of under investment in R&D, many are starved of the type of innovation that can make compelling clinical and economic impact. The appointment of Andy to the Synapse board is a fantastic endorsement for Synapse and its technology and is sure to be noticed in the industry.
Please send your comments via Twitter